Early Phase 1 N=32 Premature Fatigue in Veterans With Heart Failure: Neuronal Influences
Heart Failure
Primary: Maximal Voluntary Quadriceps Force [% Change From Baseline] — -30; -5 percentage change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 Muscle Fatigue and Scapular Sensorimotor System
Muscle; Fatigue
Primary: Change From Baseline in Scapular Proprioception — -0.48; -0.19; -0.37; -0.32 centimeters — p=0.227
N/A N=18 The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue
Fatigue
Primary: Skeletal Muscle Fatigue as Measured by Biodex 4 Pro After 4 Weeks of Placebo — 59.69; 42.07; 67.17; 63.24 Newton-Meters
N/A N=12 Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability
Fatigue · Aging
Primary: Change in Muscle Fatigue After 1 Week of Placebo or Sildenafil — 107; 115; 54; 158 percent change of successful repetitions — p=0.02
N/A N=16 Effect of Exercise on the Human Skeletal Muscle Phosphoproteome
Skeletal Muscle Protein Synthesis
Primary: Change in Acute Muscle Protein Synthesis — 143; 123 percent change
N/A N=20 Mechanisms to Reduce Mental and Physical Fatigue Following Exercise Training in Older Adults
Fatigue · Aging
Primary: Fatigue — -5.6; -4.1 change in fatigue severity score
N/A N=33 Training Effects on Skeletal Muscle Fatty Acid Metabolism
Healthy Volunteers
Primary: Insulin Sensitivity as Measured by Hyperinsulinemic Euglycemic Clamp at a Single Time Point (6 Hrs) After Intralipid or Glycerol Infusion — 8; 12; 6; 11 M value — p=<0.05
N/A N=34 Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients
Parkinson's Disease · Multiple Sclerosis
Primary: Blood Lactate Response — 1.7; 1.6; 1.2; 2.3 mmol/L
Phase 4 N=10 Examining the Effect of Burosumab on Muscle Function
X-linked Hypophosphatemia
Primary: Skeletal Muscle Adenosine Triphosphate (ATP) Synthesis Rate — 9.41 umol/g/min — p=0.4147
N/A N=22 Regulation of Muscle Protein Phenotype in Humans With Obesity
Obesity
Primary: Whole-Muscle Protein Synthesis — 0.004; 0.015 %/hr
N/A N=22 Diagnosing Intensive Care Unit (ICU) Acquired Weakness
ICU Acquired Weakness
Primary: Peak Acceleration Measured in Extensor Carpi Radialis Longus — 0.476; 1.639; 0.541; 1.608 units of Gravity
Early Phase 1 N=64 Muscadine Grape Extract to Improve Fatigue
Fatigue
Primary: Patient Reported Outcomes Measurement System (PROMIS) Fatigue 7a Questionnaire — -6.6; -5.4 score on a scale
N/A N=27 Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome
Metabolic Syndrome
Primary: Sarcoplasmic Reticulum Composition — 2.0; 2.2 PC:PE ratio
Phase 2 N=45 MitoQ for Fatigue in Multiple Sclerosis (MS)
Multiple Sclerosis · Fatigue
Primary: Modified Fatigue Inventory Scale (MFIS) — 46.5; 55.2; 54.3; 45.1 units on a scale — p=0.9489
N/A N=30 Impact of Nutritional Supplementation on Aerobic Performance and Fatigue
Performance · Fatigue
Primary: Perceived Exertion — 6.7; 7.4 units on a scale
Phase 3 N=8 ACTH for Fatigue in Multiple Sclerosis Patients
Multiple Sclerosis, Relapsing-Remitting
Primary: Fatigue at 28 Weeks — 56.50; 29.00; 55.00; 40.00 score on a scale
N/A N=30 Electrical Stimulation With Different Currents: the Effects on Force, Tolerance and Fatigue in Healthy Subjects
Healthy
Primary: Maximal Voluntary Isometric Contraction (MVIC) — 419.68 N
N/A N=15 Fatiguing Arm Exercise Following Stroke
Stroke
Primary: Short Intracortical Inhibition (SICI) — 0.83; 1.14; 0.89; 0.88 SICI ratio — p=0.15
Phase 4 N=60 The Effect of XueZhiKang on Fatigue：Comparing With Simvastatin
Dyslipidemias
Primary: Comparison Between XueZhiKang and Simvastatin on Fatigue Scores — 19.58; 21.58; 19.26; 19.33 units on a scale
N/A N=14 Muscle Capillarization and Sarcopenia
Sarcopenia
Primary: Skeletal Muscle Capillarization — 0.4; 0.2 capillaries per muscle fiber — p=0.27
N/A N=30 Nutritional Biomarkers of Sarcopenia
Sarcopenia
Primary: Resting and Maximum Plasma Leucine Concentration — 659; 755; 721; 95 micromoles per liter
N/A N=37 Forearm Immobilization, Metabolic Health, and Muscle Loss
Healthy
Primary: Percent Change in Forearm Glucose Uptake — -73; 127; -95 Percent change in clamp FGU with immob
Phase 2 N=19 Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis
Multiple Sclerosis · Internuclear Ophthalmoplegia · Fatigue
Primary: Pulse Size Ratio (PSR): Abducting/Adducting Eye Ratio for Saccadic Peak Velocity. — 1.914; 1.937; 1.805; 1.898 ratio — p=0.842672
N/A N=45 Carnosine Loading and Periodized Training in MS and HC
Multiple Sclerosis · Exercise Therapy · Dietary Supplement
Primary: VO2max — 40.4; 41.2; 44; 43.4 ml/kg/min
N/A N=590 Fatigue Management Programs for People With MS
Multiple Sclerosis
Primary: Change From Baseline in Fatigue Levels — 50.98; 56.88; 57.87 score on a scale
N/A N=22 Alternative Exercise Program to Improve Skeletal Muscle Function and Fatigue in Cancer Survivors
Breast Cancer
Primary: Maximal Calcium-activated Tension Single Muscle Fiber Tension — 185; 172; 172; 168 milliNewtons per millimeter^2
Phase 3 N=63 Enhancing Adaptations to Exercise
Inflammation
Primary: Change in Maximum Workload Muscle Strength — 7.5; 3.1 pounds
N/A N=44 Immune Function and Muscle Adaptations to Resistance Exercise in Older Adults
Sarcopenia · Aging · Immune Function
Primary: Change in Plasma Concentration of Antibodies to Pertussis Antigen (1 Week Post-vaccine) — 63.1; 63.2 units per ml — p=>0.05
Phase 4 N=19 Fade Upon TOF Stimulation Induced by Succinylcholine
Muscle Relaxants
Primary: Fade on Train of Four Stimulation — 0.85; 0.64; 0.66; 0.68 Ratio
N/A N=45 Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit
Heart Failure
Primary: Oxygen Uptake (VO2) Peak — 1778.1; 1228.2; 1393.7; 1763.6 ML/KG/Min